A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Diltiazem

Drug: MK-6916

Study type

Interventional

Funder types

Industry

Identifiers

NCT06818968

6916-005

Details and patient eligibility

About

The goal of the study is to learn what happens to levels of MK-6916 in a healthy person's body over time. Researchers will compare what happens to MK-6916 in the body when it is given with or without another medicine called diltiazem.

Enrollment

37 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

Has a body-mass index (BMI) 18 to 32 kg/m^2

Exclusion criteria

The key exclusion criteria include but are not limited to the following:

Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
Has a history of cancer (malignancy)
Has a history of cardiac arrhythmia or recurrent unexplained syncopal events
Has a first-degree relative with multiple unexplained syncopal events, unexplained cardiac arrest or sudden cardiac death, or has a known family history of an inherited arrhythmia syndrome
Has positive test(s) for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus